Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EA-3571
- Development stage
- Unknown
- Lead developer
- EA Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
EA-3571 is a small molecule, highly potent dual inhibitor of enteropeptidase and trypsin with luminal action. It is being developed for gastrointestinal and metabolic disorders, with potential anti-insulin resistance and fat-burning properties. Preclinical studies have demonstrated efficacy in mouse models of metabolic dysfunction-associated steatohepatitis (MASH)/nonalcoholic steatohepatitis (NASH). First-in-human phase 1 studies are underway to assess safety, pharmacokinetics, and pharmacodynamics in healthy volunteers. The drug is being developed by EA Pharma Co., Ltd[1][2][4][9].
- Other names
- EA-3571EA3571EA 3571
02
Targets
ENTK (Enteropeptidase)PRSS1 (Trypsin family)
Beyond the preview
Go deeper on EA-3571.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EA-3571.